How long on average can patients survive after taking furmonertinib?

Furmonertinib (Furmonertinib, trade name: Alflutinib) is a third-generation EGFRtyrosine kinase inhibitors are mainly used to treat patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC). It has shown significant efficacy in clinical studies, especially in prolonging patient survival.

In a multi-center, randomized, double-blind, parallel-controlled phase III clinical study (FURLONG study), fumetinib was used as first-line treatment for patients with locally advanced or metastatic EGFR sensitive mutationsNSCLCNSCLC pan>The median progression-free survival (PFS) of patients was 20.8 months, compared with 11.1 months in the gefitinib group, which significantly reduced the risk of disease progression or death by 56%. Although the study primarily assessed progression-free survival, its results indirectly suggest that fumetinib has the potential to extend patient survival.

Additionally, in a real-world study, 73namesEGFR mutation-positive and 2022year8 months toThe median progression-free survival for the cohort of patients with NSCLC who received fumetinib as initial treatment during 12 months in 2023 was 19.5 months (95% CI, 14.6–24.4), but median overall survival (OS) data are not yet mature. This further supports the potential of fumetinib to extend patient survival.

However, it should be noted that the efficacy of fumetinib may be affected by individual patient differences and EGFR mutation types (such as 19No. exon deletion mutation, L858R mutation, etc.) and the presence of T790M drug-resistant mutation and other factors. Therefore, in clinical application, doctors should formulate individualized treatment plans based on the patient's specific situation and combined with genetic testing results to maximize the efficacy of fumetinib.

Reference materials:https://www.drugs.com/